BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2019 10:13:56 AM | Browse: 885 | Download: 1649
 |
Received |
|
2019-03-11 08:02 |
|
Peer-Review Started |
|
2019-03-11 09:05 |
|
To Make the First Decision |
|
2019-05-06 00:10 |
|
Return for Revision |
|
2019-05-10 09:24 |
|
Revised |
|
2019-06-02 08:06 |
|
Second Decision |
|
2019-06-24 03:59 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-06-27 06:36 |
|
Articles in Press |
|
2019-06-27 06:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-07-03 01:22 |
|
Typeset the Manuscript |
|
2019-07-22 03:52 |
|
Publish the Manuscript Online |
|
2019-07-26 10:13 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ya-Li Wu, Cheng-Li Shen and Xin-Yue Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Thirteenth Five-Year Major Science and Technology Projects |
2017ZX10202201 |
| The Thirteenth Five-Year Major Science and Technology Projects |
2017ZX10201021-001-008 |
| The Capital Characteristic Clinical Application Research and Extension of Achievements |
Z151100004015181 |
| The Capital Characteristic Clinical Application Research and Extension of Achievements |
Z161100000516018 |
| The Capital Health Research and Development Projects |
2016-1-2183 |
| Special Fund for Clinical Medical Research of the Chinese Medical Association |
15030270615 |
|
| Corresponding Author |
Xin-Yue Chen, MD, Professor, International Medical Department, Beijing Youan Hospital, Capital Medical University, No. 8 of Xitoutiao Outside Youanmen, Fengtai District, Beijing 10069, China. chenxydoc@163.com |
| Key Words |
Chronic hepatitis B; Antiviral treatment endpoint; Safety; Prognosis improvement; Hepatitis B surface antigen clearance; |
| Core Tip |
Different antiviral treatment endpoints have different degrees of improvement in disease prognosis. Hepatitis B surface antigen (HBsAg) clearance has been recommended as an optimal endpoint of antiviral treatment by the latest chronic hepatitis B management guidelines. It can not only lead to safer drug withdrawal but also significantly improves prognosis. However, HBsAg clearance rate is low using the conventional single drug treatment and fixed course regimens. So individualized treatment strategies should be implemented according to the specific conditions of patients. This article reviews the different antiviral treatment endpoints in terms of the safety of drug withdrawal, improvements in prognosis and how to improve HBsAg clearance. |
| Publish Date |
2019-07-26 10:13 |
| Citation |
Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i14/1784.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i14.1784 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
